Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lefitolimod maintenance in metastatic colorectal cancer
NCT02077868Phase 3Unknown
- Sponsor
- Mologen AG
- Start
- Sep 2014
- Primary completion
- Feb 2019
- Modality
- Antisense DNA, Prophylactic Vaccines, Small Interfering RNA (siRNA)
- Countries
- 8
01
Overview
A Phase 3 trial of lefitolimod in metastatic colorectal cancer (mCRC), sponsored by Mologen AG. Status: unknown.
02
Drugs
lefitolimod
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02077868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02077868.